Lilly, Avidity to Partner on Immunology Drugs in Up-to-$440M Collaboration
Eli Lilly will use the platform of Avidity Biosciences to develop new treatments in immunology—the pharma giant’s third immunology collaboration announced in the past four months—and other unspecified “select …
Read guide →